SCHEMBL2980484

SCHEMBL2980484

CC(=O)Nc1ccc(C(=O)CBr)c(F)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.59
RAB9A P51151 4/20 0.56
CASP3 P42574 1/20 0.55
SENP8 Q96LD8 1/20 0.55
SENP7 Q9BQF6 1/20 0.55
SENP6 Q9GZR1 1/20 0.55
HDAC1 Q13547 2/20 0.53
POLB P06746 1/20 0.51
PREP P48147 1/20 0.46
SMN1; SMN2 Q16637 5/20 0.45
LMNA P02545 1/20 0.45
TDP1 Q9NUW8 1/20 0.43
IDO1 P14902 1/20 0.42
MEN1 O00255 2/20 0.42
MAPT P10636 2/20 0.42
KMT2A Q03164 2/20 0.42
HTT P42858 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ALDH1A1 P00352 1/20 0.42
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18152944 0.86 NPC1 (0.44) NPC1RAB9ACASP3SENP8SENP7
SCHEMBL9821067 0.86 POLB (0.69) NPC1RAB9ACASP3SENP8SENP7
SCHEMBL16753376 0.85 NPC1 (0.47) NPC1RAB9ACASP3SENP8SENP7
SCHEMBL15578387 0.83 NPC1 (0.57) NPC1RAB9ACASP3SENP8SENP7
SCHEMBL11263717 0.82 NPC1 (0.56) NPC1RAB9ACASP3SENP8SENP7
SCHEMBL2983642 0.82 HDAC1 (0.60) NPC1RAB9ACASP3SENP8SENP7
SCHEMBL5726045 0.81 RORC (0.52) POLBSMN1; SMN2MEN1MAPTKMT2A
SCHEMBL1966151 0.80 HDAC1 (0.58) NPC1RAB9ACASP3SENP8SENP7
SCHEMBL10757306 0.79 TDP1 (0.55) POLBSMN1; SMN2LMNATDP1MAPT
SCHEMBL20551264 0.79 ADRA2C (0.48) NPC1RAB9APOLBSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101827826-A 4-phenyl-5-oxo-imidazole derivatives, pharmaceutical compositions and uses therof NOVARTIS AG 2010-09-08 CN disclosed
CN-101827840-A Imidazolidine-2,4-dione (hydantoin) derivatives useful as npy y2 receptor modulators NOVARTIS AG 2010-09-08 CN disclosed
US-7786155-B2 Organic compounds NOVARTIS AG (CH) 2010-08-31 US disclosed
EP-2212314-A1 IMIDAZOLIDINE-2,4-DIONE (HYDANTOIN) DERIVATIVES USEFUL AS NPY Y2 RECEPTOR MODULATORS Novartis AG (CH) 2010-08-04 EP disclosed
EP-2212295-A2 4-PHENYL-5-OXO-IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEROF Novartis AG (CH) 2010-08-04 EP disclosed
WO-2009050201-A2 4-PHENYL-5-OXO-IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEROF NOVARTIS AG (CH) 2009-04-23 WO disclosed
WO-2009050200-A1 IMIDAZOLIDINE-2,4-DIONE (HYDANTOIN) DERIVATIVES USEFUL AS NPY Y2 RECEPTOR MODULATORS NOVARTIS AG (CH) 2009-04-23 WO disclosed
US-20090099243-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-04-16 US disclosed
US-20090099244-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099244-A1 ORGANIC COMPOUNDS SLCO4C1, SLC10A6, SLCO1B1 NPC1 464/4885RAB9A 3719/4885CASP3 1169/4885
US-20090099243-A1 ORGANIC COMPOUNDS SLCO4C1, SLCO1B1, SLCO1B3 NPC1 392/4885RAB9A 3557/4885CASP3 1283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.